Rachel Margolis-Goodman: Every Contribution Matters. Together, We Research Cures
Rachel Margolis-Goodman, Director of Advancement for the Versiti Blood Research Institute, shared on LinkedIn:
”It is hard to believe after a wonderful week with family and some online shopping, Giving Tuesday is here!
This past year, I decided to completely change my career and entered the fundraising world, and I am so grateful I did.
So on this giving Tuesday, perhaps you could consider giving back to the Versiti Blood Research Institute or Versiti on King!
Both the VBRI and Versiti on King is transforming blood health together!
From breakthrough research in our labs to trusted partnerships in our communities, Versiti is driving change at every level.
At Versiti Blood Research Institute, scientists are researching cures every day with the hope to eradicate blood disease.
At the VBRI we are driving breakthroughs in blood health, from stem cell biology to immunology.
This cutting edge research saves lives and will help shape the future of medicine.
Through Versiti on King (VOK), we’re connecting neighbors to resources, hosting blood typing events, community education events, and partnering with communities to improve health equity.
Through our programs this year, 170 people discovered they carry Ro-positive blood, the safest type for patients with sickle cell disease.
If you are unable to donate financially, please consider scheduling a blood donation today to help save up to 3 lives!
Every contribution matters. Together, we research cures.
Make your Giving Tuesday gift:
Stay updated on the emerging with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis